hafakot/iStock via Getty Images
Ascendis Pharma (ASND) and Visen Pharmaceuticals reported detailed results from a phase 3 trial of lonapegsomatropin (TransCon hGH) once a week, showing that it was better at increasing height than daily human growth hormone (hGH) in children with growth hormone disorder (GHD). ) in China.
The company said in May that the lawsuit had met its primary goal.
On Thursday, Visen said that the data showed that an injection once a week of lonapegsomatropin showed an increase in height (AHV) of 10.66 cm/year compared to 9.75 cm/year for daily hGH at 52 weeks.
Lonapegsomatropin met the primary objective of the trial showing that it was not inferior to daily hGH.
Another analysis showed that lonapegsomatropin was more effective than daily hGH, the company added.
Lonapegsomatropin was well tolerated with a safety profile similar to daily hGH, according to the company.
Visen pointed out that currently, most of the growth hormone drugs available on the market in China are in the form of short daily injections.
“The key 52-week results released today from the Chinese Phase 3 clinical trial show head-to-head that once-weekly lonapegsomatropin is inferior and superior to daily hGH. , and we hope to provide a new treatment option for hormonal disorders in Chinese patients.” for a long time,” said Visen CEO and Executive Director Pony LU.
Visen added that lonapegsomatropin is being developed in Greater China through a license from Ascendis using the technology of the Danish company TransCon (Transient Conjugation).
Visen has the exclusive right to develop, manufacture and sell lonapegsomatropin in Greater China, while the drug is manufactured globally by Ascendis.
Lonapegsomatropin is marketed as Skytrofa in the US, and in the EU as TransCon hGH to treat some children with GHD.
